Table 2.
Treatment 1 (mg/kg) | plus | Treatment 2 (mg/kg) | Immobility Time (sec) |
---|---|---|---|
Experiment I | |||
Vehicle | vehicle | 57.93 ± 2.02 | |
Vehicle | Km (10) | 27.73 ± 3.62 ** | |
Pcpa (100) | vehicle | 50.36 ± 4.52 | |
Pcpa (100) | Km(10) | 51.26 ± 6.24 | |
H = 10.246, df = 3, p = 0.006 | |||
Experiment II | |||
Vehicle | vehicle | 57.93 ± 2.02 | |
Pindolol (10) | Vehicle | 59.86 ± 7.83 ### | |
Vehicle | Km (10) | 29.11 ± 3.08 *** | |
Km (10) | Pindolol (10) | 13.10 ± 2.42 ***, ### | |
H = 25.77, df = 3, p ≤ 0.001 | |||
Experiment III | |||
Vehicle | vehicle | 52.93 ± 2.02 | |
Way100635 (0.03) | vehicle | 58.03 ± 5.49 | |
Vehicle | Km (10) | 29.11 ± 3.08 *** | |
Way(0.03) | Km(10) | 54.24 ± 6.85 | |
H = 14.02, df = 3, p = 0.003 | |||
Experiment IV | |||
Vehicle | vehicle | 58.13 ± 2.31 | |
Vehicle | Km (1) | 60.07 ± 3.82 | |
8OH-DPAT (0.05) | vehicle | 60.85 ± 3.85 ### | |
8OH-DPAT (0.5) | vehicle | 30.78 ± 3.48 *** | |
8OH-DPAT (0.05) | Km (1) | 34.91 ± 3.48 ***, ### | |
H = 30.59, df = 5, p = 0.001 |
Effects of joint administration of Km and PCPA (100 mg/kg daily, during the 4 days previous to the test; i.p. route), Km (oral route) plus pindolol (i.p.; 10 mg/kg) 30 min before the FST, WAY 100635 at 0.03 mg/kg (s.c.via), 30 min before Km (10 mg/kg) administration and 60 min before the FST. of Km and 8OH-DPAT, were joint administered 30 min before the start of the FST; All results are expressed as the means ± standard error (n = 8–14). Comparisons were made using a Kruskal-Wallis analysis of variance based on rank, followed by the Mann-Whitney-U-test: ** p < 0.01, *** p < 0.001 when compared with control group and ### p < 0.001 when compared with drug alone: PCPA (100) vs. [PCPA (100) plus Km (10)]: T = 80.0, n = 8–11, p = 0.967; Pindolol (10) vs. [Pindolol (10) plus Km (10)]: T = 124.0, n = 8, and n = 11, p ≤ 0.001; WAY100635 vs. [WAY100635 plus Km (10)]: T = 69.0, n = 8, p = 0.958; 8OH-DPAT (0.05) vs. [8OH-DPAT (0.05) plus Km (1)]: T = 98.0, n = 8–12, p ≤ 0.001.